Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
作者信息
ElSayed Nuha A, Aleppo Grazia, Aroda Vanita R, Bannuru Raveendhara R, Brown Florence M, Bruemmer Dennis, Collins Billy S, Cusi Kenneth, Hilliard Marisa E, Isaacs Diana, Johnson Eric L, Kahan Scott, Khunti Kamlesh, Leon Jose, Lyons Sarah K, Perry Mary Lou, Prahalad Priya, Pratley Richard E, Seley Jane Jeffrie, Stanton Robert C, Gabbay Robert A
出版信息
Diabetes Care. 2023 Sep 1;46(9):1718-1720. doi: 10.2337/dc23-ad09.
Abstract
摘要
相似文献
1
Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
Diabetes Care. 2023 Sep 1;46(9):1718-1720. doi: 10.2337/dc23-ad09.
2
Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
Diabetes Care. 2023 Sep 1;46(9):1722. doi: 10.2337/dc23-er09a.
3
Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48.
Diabetes Care. 2023 Sep 1;46(9):1716-1717. doi: 10.2337/dc23-ad08a.
4
Erratum. Comprehensive Medical Evaluation and Assessment of Comorbidities. Sec. 3. In . Diabetes Care 2017;40(Suppl. 1);S25-S32.
Diabetes Care. 2017 Jul;40(7):985. doi: 10.2337/dc17-er07. Epub 2017 May 18.
5
Addendum. 7. Diabetes Technology: . Diabetes Care 2020;43(Suppl. 1):S77-S88.
Diabetes Care. 2020 Aug;43(8):1981. doi: 10.2337/dc20-ad08c. Epub 2020 Jun 5.
6
Addendum. 2. Classification and Diagnosis of Diabetes: . Diabetes Care 2021;44(Suppl. 1):S15-S33.
Diabetes Care. 2021 Sep;44(9):2182. doi: 10.2337/dc21-ad09. Epub 2021 Jun 16.
7
Addendum. 8. Obesity Management for the Treatment of Type 2 Diabetes: . Diabetes Care 2020;43(Suppl. 1):S89-S97.
Diabetes Care. 2020 Aug;43(8):1980. doi: 10.2337/dc20-ad08b. Epub 2020 Jun 5.
8
Addendum. 11. Microvascular Complications and Foot Care: : Diabetes Care 2021;44(Suppl. 1):S151-S167.
Diabetes Care. 2021 Sep;44(9):2186-2187. doi: 10.2337/dc21-ad09b. Epub 2021 Jun 16.
9
Addendum. 10. Cardiovascular Disease and Risk Management: . Diabetes Care 2020;43(Suppl. 1):S111-S134.
Diabetes Care. 2020 Aug;43(8):1977-1978. doi: 10.2337/dc20-ad08. Epub 2020 Jun 5.
10
Addendum. 10. Cardiovascular Disease and Risk Management: . Diabetes Care 2021;44(Suppl. 1):S125-S150.
Diabetes Care. 2021 Sep;44(9):2183-2185. doi: 10.2337/dc21-ad09a. Epub 2021 Jun 16.
引用本文的文献
1
The Genetic Polymorphisms of rs161620 and rs2229611 in G6PC 3'UTR Are Associated With Metformin Efficacy in Chinese Type 2 Diabetes Mellitus.
Pharmacol Res Perspect. 2025 Apr;13(2):e70090. doi: 10.1002/prp2.70090.
2
Regional Difference of Liver Cancer in Japan: A Real-world Evidence Using the National Database of Health Insurance Claims.
Intern Med. 2025 Aug 1;64(15):2263-2269. doi: 10.2169/internalmedicine.4820-24. Epub 2025 Feb 8.
3
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
Diabetes Metab J. 2024 Nov;48(6):1015-1028. doi: 10.4093/dmj.2024.0541. Epub 2024 Nov 21.
4
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
J Gastroenterol. 2024 Dec;59(12):1120-1132. doi: 10.1007/s00535-024-02158-z. Epub 2024 Oct 11.
5
Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study.
Biomedicines. 2024 Sep 2;12(9):1993. doi: 10.3390/biomedicines12091993.
6
Nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective.
J Manag Care Spec Pharm. 2024 Sep;30(9-a Suppl):S1-S13. doi: 10.18553/jmcp.2024.30.9-a.s1.
7
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.
BMC Prim Care. 2024 Jul 20;25(1):265. doi: 10.1186/s12875-024-02517-y.
8
Glucokinase regulatory protein rs780094 polymorphism is associated with type 2 diabetes mellitus, dyslipidemia, non-alcoholic fatty liver disease, and nephropathy.
World J Diabetes. 2024 May 15;15(5):814-817. doi: 10.4239/wjd.v15.i5.814.
9
Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease.
Endocrinol Metab (Seoul). 2024 Apr;39(2):285-287. doi: 10.3803/EnM.2024.203. Epub 2024 Apr 25.
10
The Potential Role of Presepsin in Predicting Severe Infection in Patients with Diabetic Foot Ulcers.
J Clin Med. 2024 Apr 17;13(8):2311. doi: 10.3390/jcm13082311.
本文引用的文献
1
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16.
2
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
3
Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology. 2023 Jun 1;77(6):2128-2146. doi: 10.1097/HEP.0000000000000263. Epub 2023 Jan 13.
4
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis.
Gastroenterology. 2019 May;156(6):1693-1706.e12. doi: 10.1053/j.gastro.2019.01.026. Epub 2019 Jan 18.
5
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1521-1530.e8. doi: 10.1016/j.cgh.2017.04.039. Epub 2017 May 4.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
Zotero 插件